Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue

Dare Bioscience, Inc.

DSMB recommended study continue without modification after planned interim safety analysis.
~9% of treated women had experienced a pregnancy, consistent with company expectations.
~17% discontinued due to vaginal odor; no serious safety concerns or new tolerability issues.
~115 of target ~250 participants ongoing/completed; final primary endpoint uses Pearl Index.
Bayer can obtain U.S. commercialization rights with $20M payment, plus up to $310M milestones and tiered royalties.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.